Tag: Medmeme

Latest articles

Electronic prescribing to help hospitals tackle medication errors

Electronic prescribing to help hospitals tackle medication errors

Patientrack's parent company has entered into a reseller agreement with healthcare software provider Better by Marand to help hospitals tackle medication errors. Patientrack provides...
public awareness in choice of hospitals

Lack of public awareness in choice of hospitals when accessing NHS treatment

A new poll by Populus has identified a lack of public awareness in choice of hospitals when accessing NHS treatment. Populus interviewed 6116 adults online...
Seqirus to make entire influenza vaccine production process cell-based

Seqirus to make entire influenza vaccine production process cell-based

Influenza vaccine manufacturer Seqirus is to manufacture its cell-based influenza vaccine (FLUCELVAX® TETRA) using cell-based Candidate Vaccine Viruses (CVVs) for all four strains recommended...

Popular articles

pain relief patch released by nurofen

Nurofen launches a 24 hour ibuprofen pain relief patch

Nurofen announces the launch of the UK’s only 24 hour clinically proven pain relief patch containing ibuprofen.  Despite body pain being among the most commonly...
Seqirus to make entire influenza vaccine production process cell-based

Seqirus to make entire influenza vaccine production process cell-based

Influenza vaccine manufacturer Seqirus is to manufacture its cell-based influenza vaccine (FLUCELVAX® TETRA) using cell-based Candidate Vaccine Viruses (CVVs) for all four strains recommended...
positive recommendation for inotersen to treat adult patients with hATTR amyloidosis.

Tegsedi™▼ to be available on the NHS for hATTR amyloidosis

NICE issues positive recommendation for inotersen to treat adult patients with stage 1 or stage 2 polyneuropathy with hATTR amyloidosis.  Akcea Therapeutics UK Ltd., has...
final recommendation for ILUMETRI ®▼

NICE publishes final recommendation for ILUMETRI ®▼

NICE has published final recommendation for ILUMETRI ®▼ (Tildrakizumab), as a cost-effective option for adults with moderate-to-severe plaque psoriasis. The National Institute for Health and Care...
Novartis apply for Priority Review of brolucizumab

Novartis announce FDA Priority Review of brolucizumab for wet AMD

Novartis has recieved FDA filing acceptance and Priority Review of brolucizumab (RTH258) for patients with wet AMD.  Novartis has announced that the US Food and...